MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

MBX Biosciences announced positive one-year data from its open-label extension study of canvuparatide, a once-weekly PTH replacement therapy for chronic hypoparathyroidism. The drug maintained a 57% responder rate at one year with a 90% retention rate, demonstrated sustained benefits in calcium homeostasis, kidney function, and bone metabolism, and showed no new safety signals. The company remains on track to initiate Phase 3 pivotal trials in Q3 2026.

06/12/2026, 7:00 AM • GlobeNewswire

AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements

AstraZeneca announced that its investigational drug eneboparatide (AZP-3601) met the primary endpoint in the Phase 3 CALYPSO trial for chronic hypoparathyroidism. The therapy demonstrated that 31.1% of patients achieved normal calcium levels and independence from vitamin D and calcium supplements at week 24, compared to 5.9% in the placebo group. The drug was generally well-tolerated, with benefits maintained through 52 weeks, though immunogenicity was observed in some patients.

05/12/2026, 10:03 AM • Benzinga

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

MBX Biosciences announced preliminary Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug showing 7% mean weight loss at 8 weeks with good tolerability and potential for once-monthly dosing. The company also nominated MBX 5765, a novel four-agonist candidate for obesity, and achieved proof of concept for imapextide in post-bariatric hypoglycemia, though will not pursue further Phase 2b development of the latter to prioritize resources.

05/11/2026, 7:00 AM • GlobeNewswire

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MBX Biosciences announced the appointment of Karen Basbaum as Chief Business Officer and issued her an equity inducement award of 130,000 non-qualified stock options with an exercise price of $32.29 per share. The options vest over four years with a 10-year term, approved by the board as a material inducement for her employment.

04/03/2026, 8:00 AM • GlobeNewswire

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

MPM BioImpact sold its entire 1.3 million share stake in MBX Biosciences, worth $14.8 million, during Q3 2025, just before the company's pivotal clinical trials and potential key milestones in 2026.

12/03/2025, 11:10 AM • The Motley Fool

MBX Biosciences Announces Pricing of Upsized Public Offering

MBX Biosciences is conducting a public offering of 11,108,055 shares at $18.00 per share, expecting to raise approximately $199.9 million to support its precision peptide therapy development for endocrine and metabolic disorders.

09/24/2025, 9:15 PM • GlobeNewswire

MBX Biosciences Announces Proposed Public Offering

MBX Biosciences has filed a registration statement for a proposed public offering of 10 million common stock shares, with an additional option for underwriters to purchase 1.5 million shares. The offering is subject to market conditions and has major investment banks as joint book-running managers.

09/22/2025, 4:14 PM • Benzinga

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

MBX Biosciences reported successful Phase 2 trial results for canvuparatide, a potential once-weekly treatment for hypoparathyroidism, with 63% responder rate at 12 weeks and 79% at 6 months, with plans to initiate Phase 3 trials in 2026.

09/22/2025, 7:00 AM • GlobeNewswire